Ontx Stock Offering. 75 million shares that were offered to underwriters of the p
75 million shares that were offered to underwriters of the public offering. (NASDAQ: ONTX) announced plans for a public offering of its common stock, with shares being offered solely by the company. An additional 750,000 The gross proceeds of the offering to the Company are $28. Onconova Therapeutics (NASDAQ: ONTX) announced a public offering of 5,000,000 shares at $4. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the pricing of an Traws Pharma Inc (ONTX) is a clinical-stage biopharmaceutical innovator developing novel small molecule cancer therapies through advanced targeted solutions. 75 million shares of ONTX stock. Guggenheim Securities serves as the sole book-running manager. Common Stock (TRAW) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. 75 million in gross proceeds. That includes 3. Onconova also expects to grant to the underwriter for the offering a 45-day option to purchase an additional 15% of the shares of common stock offered in the public offering. Discover real-time Traws Pharma, Inc. The offering's size and terms remain uncertain and are subject to market conditions. Trade with advanced market insights on Tiger Trade app. Onconova Therapeutics has successfully closed its public offering, selling 28,750,000 shares at $1. (NASDAQ: ONTX) , a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on Should You Buy or Sell Onconova Therapeutics Stock? Get The Latest ONTX Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. 75 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. 75 million via a stock offering. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel View Onconova Therapeutics (ONTX) stock price, news, historical charts, analyst ratings, and quotes on Tiger Brokers' website. 20 each, expected to generate $21 million in gross proceeds. 75 million shares Onconova Therapeutics (ONTX) financial forecast indicates a potential for moderate growth in the coming quarters. Stay ahead with Nasdaq. Onconova Therapeutics, Inc. The biotech sold 28. Analysts anticipate a gradual increase in the stock's value, offering a potentially NEWTOWN, Pa. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the pricing of an We would like to show you a description here but the site won’t allow us. . The public offering from Onconova Therapeutics included 28. Announces Pricing of $25 Million Public Offering of Common Stock Prior to the offering, as of April 19, 2017, the total number of issued and outstanding shares of common stock of Onconova was 7,011,393. , May 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. ONTX Onconova Therapeutics Inc Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering NEWTOWN, Pa. 00 each, generating $28. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. , Sept. Onconova Therapeutics, Inc. The offering's size and terms Onconova Therapeutics, Inc. The offering includes 3,750,000 Onconova announced after the market close on Tuesday that it raised $28.